WO2014091384A3 - Compositions and methods for the treatment of mucositis - Google Patents

Compositions and methods for the treatment of mucositis Download PDF

Info

Publication number
WO2014091384A3
WO2014091384A3 PCT/IB2013/060719 IB2013060719W WO2014091384A3 WO 2014091384 A3 WO2014091384 A3 WO 2014091384A3 IB 2013060719 W IB2013060719 W IB 2013060719W WO 2014091384 A3 WO2014091384 A3 WO 2014091384A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
mucositis
treatment
oral
compositions
Prior art date
Application number
PCT/IB2013/060719
Other languages
French (fr)
Other versions
WO2014091384A2 (en
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014091384A2 publication Critical patent/WO2014091384A2/en
Publication of WO2014091384A3 publication Critical patent/WO2014091384A3/en
Priority to US14/816,089 priority Critical patent/US9840472B2/en
Priority to US15/025,562 priority patent/US11168065B2/en
Priority to US15/083,319 priority patent/US9464051B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62Quaternary ammonium compounds
    • C07C211/64Quaternary ammonium compounds having quaternised nitrogen atoms bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/50Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

The invention relates to the compounds of formula I, formula II, formula III, formula IV, formula V, formula VI and formula VII or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI or formula VII and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucositis and oral mucosal inflammatory or oral infectious diseases.
PCT/IB2013/060719 2012-12-12 2013-12-07 Compositions and methods for the treatment of mucositis WO2014091384A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/816,089 US9840472B2 (en) 2013-12-07 2015-08-03 Compositions and methods for the treatment of mucositis
US15/025,562 US11168065B2 (en) 2013-12-07 2016-01-19 Compositions and methods for the treatment of mucositis
US15/083,319 US9464051B2 (en) 2013-12-07 2016-03-29 Compositions and methods for the treatment of inflammation and pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5174CH2012 2012-12-12
IN5174/CHE/2012 2012-12-12

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14647130 A-371-Of-International 2013-12-07
US14/587,029 Continuation US9096537B1 (en) 2013-12-07 2014-12-31 Compositions and methods for the treatment of mucositis
US14/805,507 Continuation US10343994B2 (en) 2013-12-07 2015-07-22 Compositions and methods for the treatment of inflammation and pain

Publications (2)

Publication Number Publication Date
WO2014091384A2 WO2014091384A2 (en) 2014-06-19
WO2014091384A3 true WO2014091384A3 (en) 2014-12-24

Family

ID=50935043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060719 WO2014091384A2 (en) 2012-12-12 2013-12-07 Compositions and methods for the treatment of mucositis

Country Status (1)

Country Link
WO (1) WO2014091384A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147541A2 (en) * 2013-03-19 2014-09-25 Mahesh Kandula Compositions and methods for the treatment of peptic ulcers and gastrointestinal diseases
CA2973178C (en) * 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
AU2016279798B2 (en) * 2015-06-15 2021-07-08 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
CN109640965A (en) * 2016-08-11 2019-04-16 塞尔利克斯生物私人有限公司 For treating the composition and method of irritable bowel syndrome
CN111349036B (en) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 Glycopyrronium bromide substitute, and preparation method and medical application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356470A (en) * 1971-06-02 1974-06-12 Seperic Ortho-disubstituted aryl-guanidines process for their preparation and applications thereof
WO2013175377A2 (en) * 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356470A (en) * 1971-06-02 1974-06-12 Seperic Ortho-disubstituted aryl-guanidines process for their preparation and applications thereof
WO2013175377A2 (en) * 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis

Also Published As

Publication number Publication date
WO2014091384A2 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
MX2019007713A (en) Compositions and methods for the treatment of chronic pain.
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
MX2019003912A (en) Compositions and methods for the treatment of xerostomia.
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
MX2019000279A (en) Compositions and methods for the treatment of cancer.
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
MX2019006163A (en) Compositions and methods for the treatment of oral infectious diseases.
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
MX2015008661A (en) Process for the preparation of a fluorolacton derivative.
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
MX2019001360A (en) Compositions and methods for the treatment of irritable bowel syndrome.
SG10201906474QA (en) Compositions and methods for the treatment of mucositis
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2014037834A3 (en) Compositions and methods for treatment of inflammation and lipid disorders

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13862853

Country of ref document: EP

Kind code of ref document: A2